Stock to Keep Your Eyes on: Earth Science Tech Inc (ETST), CANNAGROW HLDGS IN COM USD0.001 (CGRW), United Cannabis Corp (CNAB)

Stock to Keep Your Eyes on: Earth Science Tech Inc (ETST), CANNAGROW HLDGS IN COM USD0.001 (CGRW), United Cannabis Corp (CNAB)

Stock to Keep Your Eyes on: Earth Science Tech Inc (ETST), CANNAGROW HLDGS IN COM USD0.001 (CGRW), United Cannabis Corp (CNAB)

Earth Science Tech Inc (OTCMKTS:ETST) reported the surge of 10.49% and closed at $1.79, with the total traded volume of 18,538.00 shares. During last trade its minimum price was $1.65 and it gained its highest price of $1.85 and has a total of 40.91 million outstanding shares.

On March 6, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices based company is proud to announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug completion.

At a meeting with the company’s Advisory Board on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for pre-market clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018.

The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.

CANNAGROW HLDGS IN COM USD0.001 (OTCMKTS:CGRW) showing dropped of -1.33% and closed at $1.48, after gaining total volume of 37,825.00 shares. It has total market capitalization of $153.11 million and a total of 102.07 million outstanding shares.

CANNAGROW HLDGS IN COM USD0.001 (CGRW) on March 30, 2017 announced Licensed Grower, Category One Botanicals, LLC, has completed the sale of seven (7) different strain lots for the grand opening of a High-End Recreational Dispensary located in Trinidad, Colorado.

Dr. John P. Janovec, COO, stated, “It was a natural fit from the first time we talked with the Executives of the Recreational Dispensary. They were looking to round out their inventory for a Grand Opening and Category One Botanicals had a wide variety of diverse genetic strains cured and ready for market. Blanca Mountain Green, Buffalo Diamond Kush, and Huerfano Red Bud, were among our proprietary strains included in the sale. We expect these and other proprietary strains to become some of our high-demand products throughout the Cannabis Industry in Colorado. In addition to our proprietary strains, Hemlock and White Widow – two strains already known on the market — were included in the transaction. Our combination of “name brand” and in-house private stock strains will give us an edge, and our planned breeding programs will lead to new genetic lines that will prove to be appealing to the Cannabis Community of Colorado. Relationship building is part of our equation for success. We look forward to furthering this relationship by providing a continuous supply of quality Cannabis grown in natural soil-based media and pure Colorado sunshine without the use of dangerous chemical fungicides or pesticides.”

Executives from the High-End Recreational Dispensary added, “Working with the Crew at the Colorado Buffalo Ranch Facility was an easy and seamless process. The facility is very impressive and Master Growers, Dr. John P. Janovec and Jason Wells, have the knowledge and experience in Plant Genetics that will certainly push their products into the spotlight within the Cannabis industry in Colorado. We look forward to building a long-term business relationship with Dr. John, Jason, and their Team at Category One Botanicals.”

United Cannabis Corp (OTCMKTS:CNAB) decreased -0.59% closed at $1.69 and traded with total volume of 110,090.00 shares, while the average trading remained 396,419.00 shares. During last trade its minimum price was $1.68 and it gained the highest price of $1.78. Its market capitalization was $85.60 million.

United Cannabis Corporation owns intellectual properties related to growth, production, manufacture, marketing, management, utilization, and distribution of medical and recreational marijuana, and marijuana infused products in the United States. It also provides consulting and product placement services related to marijuana industry. The company focuses on developing therapeutics, including Prana Bio Nutrient Medicinal products for supplement deficiencies related to the endocannabinoid system, including pain, neuropathy, arthritis, MS, IBS, autism, seizures, eczema, sleep, anxiety, head trauma, opioid dependency, and clinical endocannabinoid deficiencies; and Prana Aromatherapy Transdermal Roll-on line that provides targeted and large surface relief with combinations of aromatherapy. It has strategic partnerships with WeedMD RX Inc.; Harborside Health Center; and Westside Enterprises, LLC. The company also has a production and placement agreement with Jason Emo and Emotek LLC; licensing and exclusive distribution agreement with DNA Holding, LLC; and consulting and licensing agreement with Marcus Richardson. The company was formerly known as MySkin, Inc. and changed its name to United Cannabis Corporation in May 2014. United Cannabis Corporation was founded in 2007 and is based in Denver, Colorado.



Leave a reply


There are no comments on this post.

Risk Warning: Investing in digital currencies, stocks, shares and other securities, commodities, currencies and other derivative investment products (e.g. contracts for difference (“CFDs”) is speculative and carries a high level of risk. Each investment is unique and involves unique risks.

CFDs and other derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how an investment works and whether you can afford to take the high risk of losing your money.

Cryptocurrencies can fluctuate widely in prices and are, therefore, not appropriate for all investors. Trading cryptocurrencies is not supervised by any EU regulatory framework. Past performance does not guarantee future results. Any trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Your capital is at risk.

When trading in stocks your capital is at risk.

Past performance is not an indication of future results. Trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Prices may go down as well as up, prices can fluctuate widely, you may be exposed to currency exchange rate fluctuations and you may lose all of or more than the amount you invest. Investing is not suitable for everyone; ensure that you have fully understood the risks and legalities involved. If you are unsure, seek independent financial, legal, tax and/or accounting advice. This website does not provide investment, financial, legal, tax or accounting advice. Some links are affiliate links. For more information please read our full risk warning and disclaimer.